



Program Announcement for the Defense Health Agency

Parkinson's Research Program Investigator-Initiated Research Award

Funding Opportunity Number: HT942526PRPIIRA

Pre-Application Due: October 23, 2026

Application Due: November 6, 2026

This program announcement must be read in conjunction with the General Application Instructions, version [CD26_01](#).

Content

	Before You Begin	3
①	Basic Information Summarizes the <u>funding opportunity</u> , <u>funding details</u> , <u>submission deadlines and review dates</u>	4
②	Eligibility Details eligibility factors for the <u>applicant organization</u> and <u>Principal Investigator</u>	5
③	Program Description Describes the <u>program mission</u> and <u>intent of the Investigator-Initiated Research Award</u> ; provides <u>key award information</u> and <u>considerations</u> ; and outlines <u>funding details</u>	6
④	Application Contents Presents the two-step <u>application process</u> and instructions for preparing a <u>pre-application</u> and <u>full application</u>	10
⑤	Submission Requirements Provides <u>locations for application packages</u> , instructions for submitting <u>pre-applications</u> and <u>full applications</u> , and describes <u>application verification</u>	23
⑥	Application Review Information Outlines the processes for application <u>compliance review</u> , <u>pre-application</u> and <u>full application</u> selection/notification, and <u>risk assessment</u> . Also, details the review criteria for <u>pre-application screening</u> and both tiers of the CDMRP application review process – <u>Peer Review</u> and <u>Programmatic Review</u>	26
⑦	Federal Award Notices Outlines what a successful applicant can expect <u>if recommended for funding</u>	31
⑧	Post-Award Requirements References <u>policy requirements</u> for funded research; outlines <u>reporting requirements</u> and restrictions related to <u>Principal Investigator changes</u> and <u>institutional award transfers</u>	32
⑨	Other Information Outlines criteria for administrative actions including application <u>rejection</u> , <u>modification</u> , <u>withdrawal</u> and <u>withhold</u>	34
	Appendix 1 Includes a checklist for all full application components to facilitate application submission	36
	Appendix 2 Acronym List	38

Before You Begin

- **Active [SAM.gov](#), [eBRAP.org](#) and [Grants.gov](#) registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process [FAQ](#), a [Guide for Intragovernmental & Intramural Applicants](#) and a [CDMRP Video Series](#) detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

*Questions regarding
funding opportunity submission
requirements,
as well as technical assistance
related to pre-application or
intramural application submission.*

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

*Questions regarding
Grants.gov registration
and Workspace.*

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click  to be taken to additional guidance and instructions within the *General Application Instructions (GAI)*.

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#) | [Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Parkinson's Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's disease research. Research must address at least one of the four [FY26 PRP Focus Areas](#).

Distinctive Features:

- **Partnering Principal Investigator (PI) Option:** Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs.
- Preliminary data **are** required.
- Clinical trials **are** allowed.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly \$10M to fund approximately five Investigator-Initiated Research Award applications with total cost caps of \$2M per award. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), October 23, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, November 6, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, November 13, 2026
- **Peer Review:** January 2027
- **Programmatic Review:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526PRPIIRA

Assistance Listing Number: 12.420

Section Shortcuts

Basic Information | [Eligibility](#) | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

[Extramural](#) and [intramural U.S. Department of War \(DOW\)](#) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.***

2.1.2. Principal Investigator

Independent investigators at all academic levels, or equivalent, affiliated with an eligible organization are eligible to be named PI, Initiating PI, or Partnering PI on the application, regardless of ethnicity, nationality or citizenship status.

Each investigator may be named to no more than two PRP IIRA applications as either the Initiating PI or Partnering PI.

The PRP IIRA requires that the Initiating PI dedicate at least 15% of their full-time professional effort to each IIRA during the award period.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional [recipient qualification requirements](#).

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Parkinson's Research Program (PRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. In FY22, Congress transitioned the Neurotoxin Exposure Treatment Parkinson's Program to PRP and broadened the research from neurotoxin exposure treatment Parkinson's disease (PD) research to all types of PD research. Appropriations for the PRP from FY22 through FY24 totaled \$48 million (M). The FY26 appropriation is \$16M.

The vision of the PRP is to improve the health and lives of people with, or at risk for, Parkinson's disease through innovative research that translates to clinically meaningful treatments.

The mission of the PRP is to support high impact research that intends to decrease risk, slow progression, or ease symptoms of Parkinson's disease to benefit Service Members and their Families, Veterans and the general public.

The PRP seeks to support research that is relevant to the health care needs of Service Members, Veterans, and their Families, and/or Family readiness of Service Members. As such, applications must demonstrate how the proposed research will decrease the burden of Parkinson's disease on Service Members, their dependents, Veterans and other military beneficiaries (i.e. Family members of retirees). Inclusion of Service Members, Veterans, or other military beneficiary populations is not required, but the proposed research should be applicable towards and benefit those groups.

3.1. PRP Focus Areas

To meet the intent of the funding opportunity, all *applications must* address at least one of the following FY26 PRP focus areas:

- Understanding how Parkinson's disease biological and clinical heterogeneity impacts disease presentation, clinical course and therapeutic outcomes, from prodromal to late-stage Parkinson's disease.
- Development and characterization of in vitro model systems that approximate in vivo cellular and system complexity.
- Biological mechanisms or biomarkers, such as clinical, fluid, imaging, tissue, and devices, of unmet medical needs that could lead to the development of treatments for PD. Applications can utilize laboratory models through to human participants. Examples of unmet medical needs of interest include, but are not limited to:
 - Non-motor symptoms:
 - Autonomic
 - Cognitive
 - Fatigue
 - Olfaction

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Pain
- Psychiatric
- Sensory
- Sleep and circadian rhythm disruptions
- o Motor symptoms
 - Dyskinesia
 - Dystonia
 - Gait and balance
 - Tremor
- Interventions that address unmet medical needs of PD that include both clinical and preclinical models. Examples of interventions of interest include, but are not limited to:
 - o Biologicals
 - o Pharmacological
 - o Non-pharmacological
 - o Surgical
 - o Non-surgical devices
 - o Non-invasive central nervous system stimulation

3.2. Intent of the Investigator-Initiated Research Award

The PRP Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's research. This award mechanism supports the full spectrum of research from basic science through clinical trials.

3.2.1. Key Elements for the IIRA

- **Research Strategy and Feasibility:** The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of the neurodegenerative effects of PD. Experimental strategies may be novel or may be based on strong rationale derived from previously published data, presented preliminary data, or literature review. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved.

Preliminary data to support feasibility are required. Any unpublished preliminary data provided should originate from the laboratory of the PI or member(s) of the research team. The preliminary data must support the feasibility of the study.

Clinical trials may be supported by this award mechanism and require the submission of [Attachment 11, Clinical Trial Strategy](#).

- **Impact:** The proposed research, if successful, should have an impact on an area of paramount importance to PD. The application must clearly and explicitly describe the potential short-term and long-term impacts of the proposed study and convey its level of significance. The research should benefit individuals with PD.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Principal Investigator and Research Team:** The PRP seeks applications from investigators working across a broad spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research. The application should demonstrate that the research team's background is appropriate to successfully achieve the proposed specific aims and advance the PD field. **The PRP IIRA requires that the Initiating PI dedicate at least 15% of their full-time professional effort to this award during the award period.**
- **Partnering PI Option:** The IIRA includes an option for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as a Partnering PI(s). All PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to [Section 5.3, Submission Instructions](#).

3.2.2. Other Important Considerations for the IIRA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, the CDMRP does **not** support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

[Clinical trials](#), [clinical research](#) involving human subjects, secondary use of human data, and/or use of human anatomical substances are allowed within this funding opportunity.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the [STROBE](#), [CONSORT](#), [SPIRIT](#) and [ARRIVE 2.0](#) guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

[Period of Performance](#): The maximum period of performance is **3** years.

[Cost Cap](#): The application's total costs budgeted for the entire period of performance should not exceed **\$2M**.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

For Partnering PI Option (PPIO) applications, the **combined total costs** (partnering and initiating direct and indirect costs) budgeted for the entire period of performance in the applications of the Initiating PI and each Partnering PI should not exceed **\$2M**.

If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

For PPIO applications, a separate award will be made to each PI's organization.

The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for **one** PI to travel to **one** scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the PRP IIRA.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a **pre-application** submitted via the Electronic Biomedical Research Application Portal ([eBRAP](#)) and a **full application** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.



Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.



4.2. Pre-Application Components

The Initiating PI must submit the following pre-application components.

Letter of Intent (LOI) (one-page limit): Provide a brief description of the research to be conducted. Include the [FY26 PRP Focus Area\(s\)](#) under which the application will be submitted.

4.3. Full Application Components

Partnering PI Option: The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization. The application submission process for each Partnering PI uses an [abbreviated full application package](#).

4.3.1. Full Application Components for the PI or Initiating PI

Each application submission must include the completed full application package for this program announcement. See [Appendix 1](#) for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form (Grants.gov submissions only):



IMPORTANT: When completing the SF424 R&R, enter the **eBRAP log number** assigned during pre-application submission into **Block 4a – Federal Identifier**.

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the [formatting guidelines](#) in the GAI.

- **Attachment 1: Project Narrative (12-page limit): Upload as “ProjectNarrative.pdf”.**



Describe the proposed project in detail using the outline below.

- **Background:** Present the ideas and reasoning behind the proposed research. The application must provide a sound scientific rationale to support the proposed project and its feasibility as established through the demonstration of logical reasoning and critical review and analysis of published literature; include relevant literature citations. **The presentation of preliminary data to support the proposed research project**

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

is required. Any preliminary data provided should originate from the laboratory of the PI(s) or a member(s) of the research team.

- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached. State concisely the concept, theory, paradigm, and/or method that addresses an important problem in PD research and/or patient care.
- **Specific Aims:** Concisely explain the proposed research project's specific aims to be funded by this application. If the proposed research project is part of a larger study, ***present only aims that this award would fund.***
- **Research Strategy and Feasibility:** Describe the experimental design, methods, and analyses including appropriate controls, in sufficient detail for evaluation. Clearly describe how data will be collected and analyzed in a manner that is consistent with the study objectives. Consult appropriate [guidelines](#) to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Describe availability of, access to, quality control for all data and/or critical reagents, and/or cohorts, where relevant.
- If animal studies are proposed, describe how they will be conducted in accordance with the [ARRIVE guidelines 2.0](#) to achieve reproducible and rigorous results, including the choice of model and the endpoint/outcomes to be measured.
- If proposing [clinical research](#) or [clinical trial](#):
 - Describe the study population. Describe the rationale for the selection of subjects/samples/data. Explain how the selection is appropriate for addressing the study aims.
 - ***If funds for clinical research are requested***, further details of research involving human subjects or human biological substances will be required in [Attachment 10: Human Subjects/Samples Acquisition and Safety Procedures](#), as applicable.
 - ***If funds for a clinical trial are requested***, further details regarding the Clinical Trial Strategy must be described in [Attachment 11: Clinical Trial Strategy](#). *Only those proposed studies measuring safety, effectiveness, and/or efficacy of an intervention are considered clinical trials and should submit a Clinical Strategy Statement.*
 - Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group. If limiting inclusion of any group by sex, race or ethnicity, provide justification related to the scientific goals. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity should be provided as part of [Attachment 10: Human Subjects/Samples Acquisition and Safety Procedures](#) and/or [Attachment 11: Clinical Trial Strategy](#), as applicable.
 - If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the General Application Instructions, [Appendix 4](#), for additional considerations.

- **Statistical Analysis Plan:** Describe the statistical analysis plan for the resulting outcomes. If applicable, include a complete power analysis to demonstrate the sample size is appropriate to meet the objectives of the study. Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the U.S. Food and Drug Administration (FDA), if applicable.
- Address potential limitations and present alternative methods and approaches.
- Explain how the research can be completed within the proposed period of performance.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** 

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support (two-page limit per letter is recommended):** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI’s Department Chair, or appropriate organization official, should also confirm that the PI(s) meet [eligibility criteria](#). If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
- **Sex as a Biological Variable Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological

Section Shortcuts


Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the [CDMRP Directive on Sex as a Biological Variable in Research](#) for additional information.

- **Data and/or Research Sharing Plan:** Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g., for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results, including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan, which will be requested only after a recommendation for funding is made.

Refer to the [CDMRP Directive on Sharing Data and Research Resources](#) for more information about the CDMRP's expectations for making data and research resources publicly available.


- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** 

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.


- **Background:** Present the scientific rationale behind the proposed research project.
- **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached.
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Impact:** Briefly describe how the proposed research project will have short-term and/or long-term impact on PD research and/or patient care.
- **Military Relevance:** Describe how the study is relevant to military health.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** 

The lay abstract should address the points outlined below *in a manner that is readily understood by readers without a background in science or medicine*. Avoid overuse of scientific jargon, acronyms and abbreviations. **Do not duplicate the technical abstract.**

 - Summarize the objectives and rationale for the proposed research.
 - What population will the research help, and how will it help them?
 - What are the potential applications, benefits and risks of the anticipated outcomes?
 - What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
 - What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and/or their Families?
- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.** 

Refer to eBRAP for the [Suggested SOW Format](#).

For guidance on preparing the SOW, refer to the [Example: Assembling a Generic Statement of Work](#) or [Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work](#). Include milestones for data or research resource(s) sharing.

Partnering PI Option: Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and each Partnering PI(s) should be clearly noted for each task.
- **Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”.**

Articulate the pathway to making a clinical impact for individuals with, or at risk for, PD. The impact statement should address the points outlined below *in a manner that is readily understood by readers without a background in science or medicine*. Avoid overuse of scientific jargon, acronyms and abbreviations.

 - Describe a practical vision for how the short- and long-term outcomes of the proposed research will support the PRP’s mission of supporting high impact research that intends to decrease risk, slow progression or ease symptoms of Parkinson’s disease
 - The short-term impact will be the anticipated outcome(s)/product(s) from the proposed research.
 - The long-term impact may be beyond the scope of the proposed research.
 - Describe how the proposed research addresses at least one of the [FY26 PRP Focus Areas](#).
 - Explain briefly how the proposed research is relevant to the health care needs of Service Members, Veterans, their Families, and/or Family readiness of Service Members.
- **Attachment 7: Research Team Statement (one-page limit): Upload as “Team.pdf”.**

Discuss the qualifications of the research team and each individual’s specific contributions to the project, including how the appropriate expertise is incorporated to address the research question and enable the success of the proposed project.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Discuss how the PI's and other key personnel's experience, expertise, and record of accomplishment demonstrate their ability to successfully complete the proposed research project.
- Explain how the levels of effort by the PI and other key personnel are appropriate to ensuring success of the proposed research project. Clearly state if the PI is not receiving salary from the award but providing the required 15% dedication of full-time professional effort.
- Describe plans for communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among key personnel and organizations participating in the project. For multi-institutional studies, provide an organizational chart that identifies key members of the study team and provides an outline of the governing structure.
- For applications proposing a clinical trial, describe the composition of the clinical trial team. Provide details on how the team (including investigators, study coordinator, biostatistician) possesses the appropriate expertise in PD and in conducting clinical trials.

Partnering PI Option (if applicable):

- Describe how the partners' combined experience will better address the research question and explain why the work should be done together rather than through separate efforts.
- **Attachment 8: Post-Award Transition Plan (three-page limit): Upload as "Transition.pdf"**. Describe/discuss the methods and strategies proposed to move the anticipated research outcome (e.g., intervention, product, methodology, finding) to the next phase of development (e.g., clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the award. Applicants are encouraged to work with their organization's Technology Transfer Office (or equivalent) to develop the transition plan. Applicants are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. ***The Post-Award Transition Plan should include the components listed below:***
 - The project's anticipated research outcomes, including knowledge products, clinical products for development, etc.
 - A description of the necessary next logical steps to advance the research outcome to clinical implementation.
 - A timeline with defined milestones and deliverables describing the expected post-award progress of the research outcome. This timeline should include the necessary next steps to move the research outcome to the next phase of development and eventual clinical implementation.
 - A description of collaborations and other resources that are in place or will be established to execute the next steps to advance the research outcome to the next phase of development and eventual clinical implementation (e.g., clinical partners, commercial partners, manufacturing partners, clinical practice guideline development/execution committees, training providers/resources).

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Details of the funding strategy to transition to the next level of investigation, development, and/or commercialization. This may include commercial sponsorship, venture capital, federal or non-federal funding opportunities, etc.
- An assessment of the opportunities available and potential barriers that would impact the progress of commercializing and/or translating the research outcome into clinical practice.
- **Attachment 9: Animal Research Plan (only required for applications proposing animal studies; five-page limit): Upload as “AnimalResPlan.pdf”.**

If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the [ARRIVE guidelines 2.0](#) (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.
- Summarize the procedures to be conducted. Describe how the study will be controlled.
- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).
- **Attachment 10: Human Subjects/Samples Acquisition and Safety Procedures (only required if [clinical research](#) is proposed, no page limit): Upload as “HumProc.pdf”.**

Include the components listed below as applicable. Do not duplicate information from the Project Narrative.

- Describe the rationale for the proposed clinical research. Describe the endpoints to be measured and outline the proposed methodology in sufficient detail to show a clear course of action and justification. Outline what measures will be used to minimize bias, including blinding and randomization procedures. Describe any other measures taken to reduce bias. Include a description of controls, as appropriate. Outline the timing and procedures planned during the follow-up period, as appropriate.
- If the proposed clinical research was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically, **clearly articulate the portions of the clinical trial supported by this award.**

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Study Population and Recruitment Process:** Describe the study population, criteria for inclusion/exclusion and the methods that will be used for recruitment/accrual/retention of human subjects.
 - Demonstrate that the research team has access to the proposed study population. If applicable, discuss past efforts in recruiting human subjects from the target population for previous clinical studies. Address any potential barriers to accrual and plans for addressing unanticipated delays.
 - **Enrollment Distribution:** Provide anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity using the [Public Health Service \(PHS\) Inclusion Enrollment Report](#). The enrollment table(s) should be appropriate to the objectives of the study.
 - Describe how the subject-to-group assignments process will be conducted (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group or other procedures), if applicable.
 - Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study.
 - For clinical studies proposing to recruit military or VA personnel, refer to the General Application Instructions, [Appendix 4](#), for more information on recruitment process and considerations, payment and confidentiality. If a non-military non-VA population will be used for the proposed clinical study, explain how results obtained will be applicable to military or VA personnel.
- **Informed Consent Process:** Describe the plan for obtaining informed consent from human subjects. Include relevant draft process documents. **Provide a draft, in English, of the Informed Consent Form.**
- **Screening Procedures:** List and describe any evaluations that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry.
- **Risks/Benefits Assessment:** Identify all foreseeable study risks (physical, psychological, social, legal and other). Discuss the importance of the knowledge to be gained in relation to the risks to subjects. Clearly describe measures of risk management and plans for emergency response. Describe known and potential benefits, which may or may not be direct to subjects, in relation to risks.

Note: Payment and/or other compensation for participation are not considered benefits and must be addressed in Study Population and Recruitment Process.
- **Human Samples:** Describe the types and source(s) of specimens, records or data to be collected and evaluated. Include information about specimen storage (i.e., location, duration, special handling conditions). Describe the identifiers that will be associated with the human specimens and data and provide a list of who has access to subjects' identities. Describe how individually identifiable private information will be protected.
- **Statistical Plan and Data Analysis:** Describe the statistical model and data analysis plan with respect to the study objectives. Specify the approximate number of human subjects to be enrolled. Include a power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study and all proposed correlative studies. If a subpopulation of a recruited sample population will be used

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study.
- **Timeline:** State how many months into the award the anticipated clinical research would be initiated, taking into account any needed regulatory approvals (IRB and DOD Office of Human Research Oversight [OHRO, previously Human Research Protection Office]).
 - **Attachment 11: Clinical Trial Strategy (*only required for applications in which a [clinical trial](#) is proposed; no page limit*). Upload as “Clinical.pdf”.** If a Clinical Trial Strategy is included with an application that does NOT propose a clinical trial, then the Clinical Trial Strategy will be removed prior to the application being reviewed. Do not duplicate information from the Project Narrative.
 - Describe the proposed clinical trial in sufficient detail to evaluate its appropriateness and feasibility, relating to both the scientific success of the study and setting reasonable expectations for what study participants will experience. Outline the proposed methodology and study variables in sufficient detail to demonstrate a clear course of action and justification. Define each arm/study group of the proposed trial, if applicable, and describe how group assignment will occur. Provide a detailed description of the primary and any secondary or interim endpoints/outcome measures, explain why they were chosen and describe how and when they will be measured. Outline what measures will be used to minimize bias, including blinding and randomization procedures. Describe any other measures taken to reduce bias. Include a description of controls, as appropriate. Outline the timing and procedures planned during the follow-up period.
 - If the proposed clinical trial was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically, ***clearly articulate the portions of the clinical trial supported by this award.***
 - **Clinical Trial Team:** Describe the composition of the clinical trial team in enough detail to determine whether the team includes relevant subject matter expertise to accomplish the proposed work. Include any external consultants or advisors who will provide critical guidance and input to the clinical trial team (e.g., statistician, regulatory expert, commercialization consultant, clinical ethicist, patient advocate). Include study coordinator(s). Describe how the levels of effort for each individual are appropriate to successfully support the proposed clinical trial.
 - **Intervention:** Provide a description of the intervention and demonstrate the availability of the intervention for the proposed trial. Indicate who holds the intellectual property rights to the intervention, if applicable, and how the PI has obtained access to those rights for conduct of the clinical trial. As applicable, provide appropriate letters of commitment in [Attachment 2: Supporting Documentation](#) demonstrating the clinical trial team’s access to the intervention(s) for the duration of the clinical trial.
 - **Study Population and Recruitment Process:** Describe the study population, criteria for inclusion/exclusion and the methods that will be used for recruitment/accrual/retention of human subjects.
 - Demonstrate that the research team has access to the proposed study population. If applicable, discuss past efforts in recruiting human subjects from

Section Shortcuts



Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

the target population for previous clinical studies. Address any potential barriers to accrual and plans for addressing unanticipated delays.

- **Enrollment Distribution:** Provide anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity using the [PHS Inclusion Enrollment Report](#). The enrollment table(s) should be appropriate to the objectives of the study.
 - Describe how the subject-to-group assignments process will be conducted (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group or other procedures), if applicable.
 - Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study.
 - For clinical studies proposing to recruit military or VA personnel, refer to the General Application Instructions, [Appendix 4](#), for more information on recruitment process and considerations, payment and confidentiality. If a non-military non-VA population will be used for the proposed clinical study, explain how results obtained will be applicable to military or VA personnel.
- **Informed Consent Process:** Describe the plan for obtaining informed consent from human subjects. Include relevant draft process documents. **Provide a draft, in English, of the Informed Consent Form.**
- **Screening Procedures:** List and describe any evaluations that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry.
- **Risks/Benefits Assessment:** Identify all foreseeable study risks (physical, psychological, social, legal and other). Discuss the importance of the knowledge to be gained in relation to the risks to subjects. Clearly describe measures of risk management and plans for emergency response. Describe known and potential benefits, which may or may not be direct to subjects, in relation to risks.
- Note: Payment and/or other compensation for participation are not considered benefits and must be addressed in Study Population and Recruitment Process.**
- **Regulatory Documentation:** For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international Regulatory Agency unless otherwise noted.
- **For products/interventions that DO NOT require regulation by a Regulatory Agency:** Provide evidence that the clinical trial does not require regulation by a Regulatory Agency. Submissions providing “not applicable,” “none,” or similar responses do not satisfy this request. No further regulatory documentation is required.
 - **For products that DO require regulation by a Regulatory Agency:** If the product is not currently FDA-approved, -licensed or -cleared, and requires an Investigational New Drug/Investigational Device Exemption (IND/IDE) or equivalent, provide detailed plans for an FDA IND/IDE application submission **within 60 days of the award**. The IND or IDE should be specific for the investigational product (i.e., not a derivative or alternate version of the product) and indication tested in the proposed study. Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- If available, provide documentation that:
 - ❖ Indicates the date of Regulatory Agency submission, application number and sponsor for any existing FDA applications in place.
 - ❖ Supports the feasibility of acquiring an active IND or IDE (and/or international equivalent) for the product.
 - ❖ Shows the communication from the FDA indicating the IND or IDE application is active/safe to proceed.
- **Statistical Plan and Data Analysis:** Describe the statistical model and data analysis plan with respect to the study objectives. Specify the approximate number of human subjects to be enrolled. Include a power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study and all proposed correlative studies. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study. Ensure sufficient information is provided to allow thorough evaluation of all statistical calculations during review of the application.
- **Timeline:** State how many months into the award the anticipated clinical trial would be initiated, taking into account any clinical trial preparation (IRB and DOD OHRO, previously Human Research Protection Office approval). **Note: The clinical trial must begin within the first year of the award.**
- **Attachment 12: Representations (*Grants.gov submissions only*): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the [Required Representations](#) document available on eBRAP. 
- **Attachment 13: Suggested Intragovernmental/Intramural Budget Form (*if applicable*): Upload as “IGBudget.pdf”.** If an [intramural DOW organization](#) will be a collaborator in the performance of the project, complete a separate budget for that organization using the [Suggested Intragovernmental/Intramural Budget](#) form available on eBRAP. 

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information



Grants.gov



eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI(s) even if they are located within the same organization. Refer to [Section 3.4, Funding Details](#), for detailed information.

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.3.2. Full Application Components for each Partnering PI

Refer to the equivalent attachment above for details specific to each of the following application components. See [Appendix 1](#) for a checklist of the full application components required for each Partnering PI.

(a) SF424 Research & Related Application for Federal Assistance Form (*Grants.gov Submissions Only*):

(b) Attachments:

- **[Attachment 5](#): Statement of Work (three-page limit): Upload as “SOW.pdf”.** Each PI must submit an identical copy of a jointly created SOW.
- **[Attachment 12](#): Representations (*Grants.gov submissions only*): Upload as “RequiredReps.pdf”.**
- **[Attachment 13](#): Suggested Intragovernmental/Intramural Budget Form: Upload as “IGBudget.pdf”.**

(c) [Additional Application Materials](#):

The following are additional application materials for application submission. Follow the instructions specific to the submission portal found within the GAI.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information



Grants.gov



eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Partnering PI(s) should not include budget information for the Initiating PI, or vice versa, even if they are located within the same organization. Refer to [Section 3.4, Funding Details](#), for detailed budget information.

iii. Project/Performance Site Location(s) Form

iv. Research & Related Subaward Budget Attachment(s) Form *(if applicable, Grants.gov submissions only)*

4.4. Other Application Elements

If recommended for funding, a quad chart and data management plan compliant with Section 3.c, Enclosure 3, [DoD Instructions 3200.12](#) will be requested.



The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526PRPIIRA from [Grants.gov](#) or [eBRAP](#), depending on which submission portal will be used.


5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), [SAM.gov](#), and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration. i

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI or Initiating PI through [eBRAP](#), including the submission of contact information for each Partnering PI if selecting either Partnering PI option. i

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during [the full application submission process](#). The eBRAP log

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the [eBRAP Help Desk](#) if any changes need to be made.

When starting the pre-application, the PI or Initiating PI should select a Mechanism Option appropriate to their pre-application:

Application Includes:	Select Mechanism Option:
Single PI and No Clinical Trial	No Option
Single PI and Clinical Trial	Clinical Trial
Initiating PI and Partnering PI with No Clinical Trial	Partnering PI Option
Initiating PI and Partnering PI with Clinical Trial	Partnering PI Option – Clinical Trial


Partnering PI Option:

After the Initiating PI confirms submission of the pre-application, the Partnering PI(s) will be notified of the pre-application submission via an email from eBRAP. **The Partnering PI(s) must follow the instructions provided in the email to associate the partnering pre-application with their eBRAP account.** If not previously registered, the Partnering PI(s) must register in eBRAP.

Partnering PIs should not initiate a new pre-application based on the same research project submitted by the Initiating PI. Partnering PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:


- Any intramural Partnering PI will not be able to submit their full application package components to eBRAP.
- The Partnering PI(s) will not be able to view and modify their full application during the verification period in eBRAP.

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace. 

eBRAP Submissions: Only [intramural DOW organizations](#) may submit full applications through eBRAP. 

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. **The Project Narrative and Research & Related Budget Form cannot be changed after the** 

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

application submission deadline. Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the [application verification period](#) ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in [Section 1, Basic Information](#).

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the [CDMRP's Directive on Research Duplication](#).

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns may result in application withdrawal.



Members of the FY26 PRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members **may** provide [letters](#) to confirm [PI eligibility](#) and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the [FY26 PRP Programmatic Panel members](#) can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in [Section 9.2, Administrative Actions](#).

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Research Strategy and Feasibility**
 - How well the preliminary and/or published data, relevant literature, and scientific rationale support the proposed research project.
 - To what extent the proposed research project is feasible as described, and according to the statistical analysis plan.
 - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single-sex study is sufficiently strong.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- If animal studies are included, how well studies are designed to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured.
- If human subjects or human biological samples will be used, how well the plan for the recruitment of subjects, including women and minorities, or the acquisition of samples is justified and appropriate to accomplish the proposed work.
- How well the application identifies potential problems and addresses alternative approaches.
- How well the SOW indicates a feasible plan and timeline to conduct the research and provides clearly defined research milestones to be accomplished by the end of each year in the period of performance.
- **Impact**
 - To what degree the proposed short- and long-term outcomes of the proposed research will support the PRP's mission of supporting high impact research that intends to decrease risk, slow progression or ease symptoms of Parkinson's disease
 - How well the proposed research addresses one or more of the [FY26 PRP Focus Areas](#).
 - To what extent the proposed research is relevant to the health care needs of Service Members, Veterans, their Families, and/or Family readiness of Service Members.
- **Personnel**
 - **Principal Investigator and Research Team**
 - To what degree the PI's and other team members' experience, expertise, and record of accomplishment demonstrate their ability to successfully complete the proposed research project.
 - To what extent the levels of effort by the PI and other key personnel are appropriate to ensure success of the proposed research project.
 - Whether the application proposes at least 15% dedication of full-time professional effort of the PI to this award.
 - If applicable, to what extent the clinical team possesses the appropriate expertise in PD and in conducting clinical trials.
 - **Partnering PI Option**
 - How well the partners bring different strengths to the application.
 - How the partners' combined expertise will better address the research question.
- **Post-Award Transition Plan**
 - To what extent the Post-Award Transition Plan outlines the project's anticipated research outcome(s) and/or product(s).
 - To what extent the plan describes the next logical steps to be taken by the research team to advance the anticipated research outcome(s)/product(s) to the next stage of development.
 - To what extent the plan describes collaborations and other resources that are in place or will be established during the period of performance to execute the proposed next logical steps.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- To what extent the plan describes the methods and strategies necessary for the research outcome/product to impact survivorship care and/or outcomes and whether the plan provides a timeline with defined milestones.
- To what extent the plan describes the funding strategy necessary to transition the outcomes of the overall program to the next level of investigation, development and/or implementation.
- To what extent the plan discusses the opportunities available and potential barriers that would impact the progress of commercializing and/or translating the research outcome(s)/products(s) into clinical practice/public utility.
- If applicable, to what extent the application discusses ownership rights and/or access to the intellectual property necessary for the development and/or commercialization of products or technologies supported under this award.

For applications with a clinical trial, the following additional **Clinical Trial Strategy** review criteria will be evaluated:

- **Clinical Trial Strategy**

- To what extent the intervention is clearly identified, and appropriate endpoints are described.
- To what extent the application demonstrates availability of the intervention and indicates who holds the intellectual property rights to the intervention.
- To what extent the clinical trial design is best suited to answer the proposed research question.
- To what extent the study population and inclusion/exclusion criteria are well-described. To what extent the recruitment process and barriers to participation are described in detail.
- To what extent the proposed clinical trial methodology and study variables are outlined in sufficient detail to demonstrate a clear course of action and justification. Whether sufficient detail is provided in chronological order for a person uninvolved in the study to understand what the human participant will experience.
- If applicable, how well the application describes whether the proposed clinical trial was initiated using other funding prior to this application and whether the portions of the study supported with funds from this award are clearly articulated.
- If applicable, to what extent the application describes how data will be reported and how it will be assured that the documentation will support a regulatory filing.
- To what extent the application includes appropriate plans and/or documentation in support of Regulatory Agency submissions and/or approvals.
- Whether the detailed plans for initiating the clinical trial within the first year are feasible.

In addition, the following criteria will also contribute to the overall evaluation of the application but will not be individually scored and are therefore termed **unscored criteria**.

Unscored criteria are not assigned numerical scores but are evaluated qualitatively and may be discussed during panel review. Significant strengths or weaknesses in unscored criteria may influence the overall score and funding recommendation. For example, an inadequate budget or poorly written application may reduce confidence in the application despite strong scored criteria.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- **Budget**
 - Whether the budget is appropriate for the proposed research.
- **Environment**
 - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
 - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Data and/or Research Sharing Plan**
 - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.
- **Application Presentation**
 - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 PRP, as evidenced by the following:
 - Adherence to the intent of the funding opportunity
 - Program portfolio balance
 - Relative impact
 - Programmatic relevance to [FY26 PRP Focus Areas](#)

6.3. Application Review and Selection Process

6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. ***The CDMRP will NOT provide an invitation to submit a full application after pre-application submission.*** Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section 6.2.3, Programmatic Review](#).*** Additional information about the two-tier process used by the CDMRP can be found on the [CDMRP website](#).

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a [limited time period](#) based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the [DOD Component Decision Matrix](#) must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | [Federal Award Notices](#) | Post-Award Requirements | Other Information


7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the PRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable [database](#).

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official. 

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

8. Post-Award Requirements


8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding [administrative requirements](#) and [national policy requirements](#).

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [DHACA Terms and Conditions](#) for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local IACUC, IRB or Ethics Committee (EC) review. 

Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219. Additionally, the CDMRP requires all funded clinical trials to register and submit study results on [ClinicalTrials.gov](#).

8.2. Reporting

Annual technical progress reports and quad charts, as well as a final technical progress report and quad chart, will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

PHS Inclusion Enrollment Reporting (only required for [clinical research studies](#) and [clinical trials](#)): Enrollment reporting on the basis of sex, race, and/or ethnicity using the PHS Inclusion Enrollment Report will be required with each annual and final progress report. The [PHS Inclusion Enrollment Report](#) is available on eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable [Representations](#).

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.



An organizational transfer of an award supporting a clinical trial is strongly discouraged and, in most cases, will not be allowed. Approval of a transfer request will be on a case-by-case basis.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- The Pre-application was not submitted.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the [FY26 PRP Programmatic Panel](#) is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the [CDMRP website](#).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization):
(a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The PI does not meet the [eligibility criteria](#).
- Failure to submit all associated (Initiating and Partnering PI) applications by the deadline.
- The application does not address at least one of the [FY26 PRP Focus Areas](#).
- More than two applications name the same investigator as the PI. Only the first two applications received will be accepted; additional applications will be administratively rejected.
- The application proposes animal studies but is missing [Attachment 9: Animal Research Plan](#).
- The application proposes a clinical trial but is missing [Attachment 11: Clinical Trial Strategy](#).

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	Single PI	Partnering PI
SF424 Research & Related Application for Federal Assistance <i>(Grants.gov submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
Summary (Tab 1) and Application Contacts (Tab 2) <i>(eBRAP submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
Attachments		
Project Narrative – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>	
Supporting Documentation – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>	
Technical Abstract – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>	
Lay Abstract – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>	
Statement of Work – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Impact Statement – Attachment 6, upload as “Impact.pdf”	<input type="checkbox"/>	
Research Team Statement – Attachment 7, upload as “Team.pdf”	<input type="checkbox"/>	
Post-Award Transition Plan – Attachment 8, upload as “Transition.pdf”	<input type="checkbox"/>	
Animal Research Plan – Attachment 9, upload as “AnimalResPlan.pdf”	<input type="checkbox"/>	
Human Subjects/Samples Acquisition and Safety Procedures – Attachment 10, upload as “HumProc.pdf”	<input type="checkbox"/>	
Clinical Trial Strategy – Attachment 11, upload as “Clinical.pdf”	<input type="checkbox"/>	
Representations <i>(Grants.gov submissions only)</i> – Attachment 12, upload as “RequiredReps.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Suggested Intragovernmental/Intramural Budget Form <i>(if applicable)</i> – Attachment 13, upload as “IGBudget.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Additional Application Materials		
Research & Related Senior/Key Person Profile (Expanded)	<input type="checkbox"/>	<input type="checkbox"/>
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Budget	<input type="checkbox"/>	<input type="checkbox"/>
Project/Performance Site Location(s)	<input type="checkbox"/>	<input type="checkbox"/>

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Research & Related Subaward Budget Attachment(s) (<i>if applicable</i>)	<input type="checkbox"/>	<input type="checkbox"/>
--	--------------------------	--------------------------

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
ACURO	Animal Care and Use Review Office
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CONSORT	Consolidated Standards of Reporting Trials
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FDA	U.S. Food and Drug Administration
FY	Fiscal Year
GAI	General Application Instructions
IACUC	Institutional Animal Care and Use Committee
IDE	Investigational Device Exemption
IND	Investigational New Drug
IIRA	Investigator-Initiated Research Award
IRB	Institutional Review Board
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
OHRO	Office of Human Research Oversight (previously Human Research Protection Office)
ORRC	Office of Research and Regulatory Compliance
PD	Parkinson's Disease
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PRP	Parkinson's Research Program

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
STROBE	STrengthening the Reporting of OBservational Studies in Epidemiology
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs